Cantabio Pharmaceuticals Inc. is a preclinical stage biotechnology company. The Company is focused on commercializing therapies and the intellectual property generated from its research and development activities for Parkinsonâs disease (PD), Alzheimerâs disease (AD) and other related neurodegenerative diseases. The Companyâs small molecule therapy candidates program (CB101) and protein therapy candidate (CB201) targets Parkinsonâs disease and a range of neurodegenerative diseases including Alzheimerâs disease, amyotrophic lateral sclerosis (ALS), Huntingtonâs disease and stroke. It also has two additional small molecule pharmacological chaperone programs for the treatment of Alzheimerâs Disease (and other related dementias); CB301, targeting the Tau protein, for the development of Alzheimerâs therapeutics, and CB401, targeting the AÃ peptide in Alzheimerâs drug research. The Companyâs strategy integrates therapeutic focus on targeting family biophysics and drug discovery technology.
More about the company